Skip to main
RAPP

RAPP Stock Forecast & Price Target

RAPP Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rapport Therapeutics is well-positioned for success with a strong pipeline of programs targeting neurological and psychiatric disorders. The recent modification of the statistical analysis plan and increase in target enrollment for the Phase 2 bipolar mania trial demonstrate the company's commitment to producing robust clinical evidence and potentially positioning the trial as confirmatory evidence of effectiveness. Additionally, RAP-219's mechanism of action is well-aligned with the neurobiology of bipolar mania and offers a differentiated profile relative to current treatments, which could potentially lead to high demand in the market. The company's strong performance in early clinical trials and the positive safety and tolerability profile of RAP-219 also bode well for their future success in the epilepsy and bipolar disorder markets.

Bears say

Rapport Therapeutics is a clinical-stage biotechnology company with a portfolio of novel programs aimed at treating neurological and psychiatric disorders. While the company has promising data for its lead candidate, RAP-219, in treating focal onset seizures and bipolar mania, there is considerable competition in these markets and success is not guaranteed. Additionally, the company's reliance on external funding and potential manufacturing challenges could pose risks for its pipeline advancement. As a result, the company's stock may face challenges in generating significant returns for investors.

RAPP has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rapport Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rapport Therapeutics Inc (RAPP) Forecast

Analysts have given RAPP a Buy based on their latest research and market trends.

According to 6 analysts, RAPP has a Buy consensus rating as of May 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $48.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $48.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rapport Therapeutics Inc (RAPP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.